Latest Cancer News

FDA Grants Breakthrough Therapy Designation to AP26113 for ALK-Positive NSCLC (10-22-2014)
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to an investigational agent AP26113 for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non–small... Continue Reading

Adding Cediranib to Olaparib Markedly Improves Progression-Free Survival but Increases Toxicity in Recurrent Platinum-Sensitive Ovarian Cancer (10-21-2014)
The addition of the antiangiogenic agent cediranib to the PARP inhibitor olaparib in women with recurrent platinum-sensitive ovarian cancer improves time to cancer progression and survival. The results... Continue Reading

Second-line Avastin Improves Progression-Free Survival in Advanced HER2-Negative Breast Cancer (10-20-2014)
Adding Avastin® (bevacizumab) to chemotherapy in second-line treatment of advanced HER2-negative breast cancer improves progression-free survival. Results of the phase III TANIA trial evaluating the role... Continue Reading

United in Healing